Loading...
[(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
Glicksman, RM Metser, U Valliant, J Chung, PW Fleshner, NE Bristow, Robert G Green, D Finelli, A Hamilton, R Stanescu, T
Glicksman, RM
Metser, U
Valliant, J
Chung, PW
Fleshner, NE
Bristow, Robert G
Green, D
Finelli, A
Hamilton, R
Stanescu, T
Citations
Altmetric:
Abstract
Description
Date
2020
Publisher
Collections
Files
Loading...
Open Access
Adobe PDF, 517.01 KB
Keywords
Type
Article
Citation
Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, et al. [(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open. 2020;10(4):e035959.